OS THERAPIES INCORPORATED Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
OS THERAPIES INCORPORATED (OSTX) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$64.80 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-14
- OS THERAPIES INCORPORATED cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $647.72K.
- OS THERAPIES INCORPORATED cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$2.56M, a 4283.77% decline year-over-year.
- OS THERAPIES INCORPORATED cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $61.25K, a 66.66% decline year-over-year.
- OS THERAPIES INCORPORATED cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was $183.73K.
- OS THERAPIES INCORPORATED cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$5.26M, a 195.78% decline from fiscal 2024.
- OS THERAPIES INCORPORATED cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $5.50M.
- OS THERAPIES INCORPORATED cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$132.50K.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$64.80K 10-Q · filed 2026-08-14 | ||||
| 2026-03-31 | $647.72K 10-Q · filed 2026-05-18 | ||||
| 2025-12-31 | -$5.26M 10-K · filed 2026-03-31 | ||||
| 2025-09-30 | -$3.66M 10-Q · filed 2025-11-14 | ||||
| 2025-06-30 | -$2.73M 10-Q · filed 2026-08-14 | ||||
| 2025-03-31 | -$2.56M 10-Q · filed 2026-05-18 | ||||
| 2024-12-31 | $5.50M 10-K · filed 2026-03-31 | $5.49M 10-K · filed 2025-03-31 | |||
| 2024-09-30 | $1.82M 10-Q · filed 2025-11-14 | ||||
| 2024-06-30 | $55.94K 10-Q · filed 2025-08-18 | ||||
| 2024-03-31 | $61.25K 10-Q · filed 2025-05-15 | ||||
| 2023-12-31 | -$132.50K 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | -$155.42K 10-Q · filed 2024-11-15 | ||||
| 2023-06-30 | -$122.26K 10-Q · filed 2024-08-14 | ||||
| 2023-03-31 | $183.73K 10-Q · filed 2024-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |